focus -WSS

focus

author：leisure time 2025-09-03 05:25:45 - browse：2928

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Microbiome research is starting to find links to chronic diseases

WSS

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Thermo Fisher plant for manufacturing gene therapies to expand

Study gives hint on South Asians’ higher risk of cardiovascular disease

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Intarcia’s device

FDA panel to weigh approval of NurOwn, controversial ALS drug

focus

focus

explore

In age of alternative facts, a scholarly course on calling out crap

How AI helped researchers track recovery from depression

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Having children helps parents live longer, especially after age 80

DIEP, the 'gold standard' of breast reconstruction, is under threat

Juul documents reveal insider tactics on political lobbying

In Memoriam: Notable people who died in 2023

Why Eli Lilly’s earnings didn’t quite live up to the hype

Medicare proposal to cover medical devices draws a mixed reaction

Changes to biosimilar regulatory framework must prioritize patients

Wikipedia

Microbiome research is starting to find links to chronic diseases

Senators: Long

Ukraine and a new approach to mental health in war

Changes to biosimilar regulatory framework must prioritize patients

Bernie Sanders gets little from pharma CEOs on drug prices

How Vertex's cystic fibrosis drug is changing patients' lives

explore

entertainment

hotspot

hotspot